1. Home
  2. BQ vs BOLT Comparison

BQ vs BOLT Comparison

Compare BQ & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boqii Holding Limited representing

BQ

Boqii Holding Limited representing

HOLD

Current Price

$0.81

Market Cap

7.7M

ML Signal

HOLD

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$3.56

Market Cap

7.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BQ
BOLT
Founded
2008
2015
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
7.1M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
BQ
BOLT
Price
$0.81
$3.56
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$34.00
AVG Volume (30 Days)
43.0K
27.2K
Earning Date
01-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,695,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$133.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.07
52 Week Low
$0.65
$3.13
52 Week High
$72.74
$7.20

Technical Indicators

Market Signals
Indicator
BQ
BOLT
Relative Strength Index (RSI) 41.05 36.50
Support Level $0.70 $3.14
Resistance Level $0.89 $4.33
Average True Range (ATR) 0.04 0.36
MACD -0.01 -0.05
Stochastic Oscillator 1.67 11.90

Price Performance

Historical Comparison
BQ
BOLT

About BQ Boqii Holding Limited representing

Boqii Holding Ltd is a pet-focused platform in China. It offer a truly one-stop destination that pet parents in China may go to get everything it need for their pets and share their passion for pet parenting. It operate a pet-focused online retail business in China's pet market in terms of GMV. The company operates in single segment. This segment is engaged in pet products sales and online marketing and information services and other. All the company's revenues is derived from The PRC.

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Share on Social Networks: